Literature DB >> 19776560

Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease.

K L Raphael1, K A Strait, P K Stricklett, B C Baird, K Piontek, G G Germino, D E Kohan.   

Abstract

BACKGROUND/AIMS: Cystic epithelia in polycystic kidney disease display features similar to malignant cells. Thiazolidinediones have been shown to have anti-neoplastic properties, therefore we tested the hypothesis that pioglitazone reduces cyst formation, improves renal function, and prolongs survival in a mouse model of polycystic kidney disease.
METHODS: PC-Pkd1-KO mice, which have homozygous mutations of the Pkd1 gene in principal cells, were used. On the day after giving birth, mothers were fed standard mouse chow with or without pioglitazone (30 mg/kg chow). After weaning, the assigned diet was continued. At 1 month of age, blood pressure was measured and animals were sacrificed to determine kidney weight, body weight, and serum urea. Kidneys were evaluated for proliferation using Ki-67, apoptosis using TUNEL analysis, and cyst number using MRI. Survival was observed.
RESULTS: Pioglitazone did not alter renal function, cell proliferation, apoptosis, or cyst formation in animals with polycystic kidney disease, however it did increase survival. Pioglitazone reduced blood pressure in PC-Pkd1-KO, but not in controls.
CONCLUSION: These findings suggest that pioglitazone may have a unique antihypertensive effect in polycystic kidney disease, and that such an effect may promote improved survival. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19776560      PMCID: PMC2818398          DOI: 10.1159/000242432

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  17 in total

1.  Effects of pioglitazone and candesartan on renal fibrosis and the intrarenal plasmin cascade in spontaneously hypercholesterolemic rats.

Authors:  Fumihiro Omasu; Takashi Oda; Muneharu Yamada; Nobuyuki Yoshizawa; Kazuo Yamakami; Yutaka Sakurai; Soichiro Miura
Journal:  Am J Physiol Renal Physiol       Date:  2007-08-01

Review 2.  Polycystic kidney disease: cell division without a c(l)ue?

Authors:  M Simons; G Walz
Journal:  Kidney Int       Date:  2006-06-28       Impact factor: 10.612

3.  Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.

Authors:  YouFei Guan; Chuanming Hao; Dae Ryong Cha; Reena Rao; Wendell Lu; Donald E Kohan; Mark A Magnuson; Reyadh Redha; Yahua Zhang; Matthew D Breyer
Journal:  Nat Med       Date:  2005-07-10       Impact factor: 53.440

4.  Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention.

Authors:  Hui Zhang; Aihua Zhang; Donald E Kohan; Raoul D Nelson; Frank J Gonzalez; Tianxin Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-14       Impact factor: 11.205

5.  Pioglitazone mitigates renal glomerular vascular changes in high-fat, high-calorie-induced type 2 diabetes mellitus.

Authors:  Walter E Rodriguez; Neetu Tyagi; Irving G Joshua; John C Passmore; John T Fleming; Jeff C Falcone; Suresh C Tyagi
Journal:  Am J Physiol Renal Physiol       Date:  2006-04-11

6.  Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone.

Authors:  Hisashi Makino; Yoshihiro Miyamoto; Kazutomo Sawai; Kiyoshi Mori; Masashi Mukoyama; Kazuwa Nakao; Yasunao Yoshimasa; Shin-ichi Suga
Journal:  Diabetes       Date:  2006-10       Impact factor: 9.461

7.  Inactivation of Pkd1 in principal cells causes a more severe cystic kidney disease than in intercalated cells.

Authors:  Kalani L Raphael; Kevin A Strait; Peter K Stricklett; R Lance Miller; Raoul D Nelson; Klaus B Piontek; Gregory G Germino; Donald E Kohan
Journal:  Kidney Int       Date:  2009-01-14       Impact factor: 10.612

8.  Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats.

Authors:  Gang Jee Ko; Young Sun Kang; Sang Youb Han; Mi Hwa Lee; Hye Kyoung Song; Kum Hyun Han; Hyoung Kyu Kim; Jee Young Han; Dae Ryong Cha
Journal:  Nephrol Dial Transplant       Date:  2008-04-03       Impact factor: 5.992

9.  Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.

Authors:  Arlene B Chapman; Lisa M Guay-Woodford; Jared J Grantham; Vicente E Torres; Kyongtae T Bae; Deborah A Baumgarten; Philip J Kenney; Bernard F King; James F Glockner; Louis H Wetzel; Marijn E Brummer; W Charles O'Neill; Michelle L Robbin; William M Bennett; Saulo Klahr; Gladys H Hirschman; Paul L Kimmel; Paul A Thompson; J Philip Miller
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

10.  Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model.

Authors:  S Ohtomo; Y Izuhara; S Takizawa; N Yamada; T Kakuta; C van Ypersele de Strihou; T Miyata
Journal:  Kidney Int       Date:  2007-09-26       Impact factor: 10.612

View more
  14 in total

Review 1.  Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) - A new therapeutic option?

Authors:  Marcus D Säemann; Michael Krebs
Journal:  Wien Klin Wochenschr       Date:  2010-04       Impact factor: 1.704

2.  Thiazolidinediones inhibit MDCK cyst growth through disrupting oriented cell division and apicobasal polarity.

Authors:  Zhiguo Mao; Andrew J Streets; Albert C M Ong
Journal:  Am J Physiol Renal Physiol       Date:  2011-03-23

3.  Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists.

Authors:  Stephanie M Flaig; Vincent H Gattone; Bonnie L Blazer-Yost
Journal:  J Transl Int Med       Date:  2016-09-23

Review 4.  Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.

Authors:  Peter C Harris; Vicente E Torres
Journal:  J Clin Invest       Date:  2014-06-02       Impact factor: 14.808

5.  Adenylyl cyclase 6 deficiency ameliorates polycystic kidney disease.

Authors:  Sara Rees; Wararat Kittikulsuth; Karl Roos; Kevin A Strait; Alfred Van Hoek; Donald E Kohan
Journal:  J Am Soc Nephrol       Date:  2013-10-24       Impact factor: 10.121

6.  PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.

Authors:  Daisuke Yoshihara; Hiroki Kurahashi; Miwa Morita; Masanori Kugita; Yoshiyuki Hiki; Harold M Aukema; Tamio Yamaguchi; James P Calvet; Darren P Wallace; Shizuko Nagao
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-08

7.  Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.

Authors:  Bonnie L Blazer-Yost; Julie Haydon; Tracy Eggleston-Gulyas; Jey-Hsin Chen; Xiaofang Wang; Vincent Gattone; Vicente E Torres
Journal:  PPAR Res       Date:  2010-11-01       Impact factor: 4.964

Review 8.  Experimental therapies and ongoing clinical trials to slow down progression of ADPKD.

Authors:  Maria V Irazabal; Vicente E Torres
Journal:  Curr Hypertens Rev       Date:  2013-02

Review 9.  The cell biology of polycystic kidney disease.

Authors:  Hannah C Chapin; Michael J Caplan
Journal:  J Cell Biol       Date:  2010-11-15       Impact factor: 10.539

10.  Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective.

Authors:  Anish A Kanhai; Hester Bange; Lotte Verburg; Kyra L Dijkstra; Leo S Price; Dorien J M Peters; Wouter N Leonhard
Journal:  Sci Rep       Date:  2020-02-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.